|
1
|
Yang K, Li Z, Chen Y, Yin F, Ji X, Zhou J,
Li X, Zeng T, Fei C, Ren C, et al: Na, K-ATPase α1 cooperates with
its endogenous ligand to reprogram immune microenvironment of lung
carcinoma and promotes immune escape. Sci Adv. 9:eade53932023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hinterleitner C, Strähle J, Malenke E,
Hinterleitner M, Henning M, Seehawer M, Bilich T, Heitmann J, Lutz
M, Mattern S, et al: Platelet PD-L1 reflects collective
intratumoral PD-L1 expression and predicts immunotherapy response
in non-small cell lung cancer. Nat Commun. 12:70052021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aguiar PN Jr, Santoro IL, Tadokoro H, de
Lima Lopes G, Filardi BA, Oliveira P, Mountzios G and de Mello RA:
The role of PD-L1 expression as a predictive biomarker in advanced
non-small-cell lung cancer: A network meta-analysis. Immunotherapy.
8:479–488. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aguiar PN Jr, De Mello RA, Hall P,
Tadokoro H and de Lopes G: PD-L1 expression as a predictive
biomarker in advanced non-small-cell lung cancer: Updated survival
data. Immunotherapy. 9:499–506. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim H and Chung JH: PD-L1 Testing in
non-small cell lung cancer: Past, present, and future. J Pathol
Transl Med. 54:1962019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico
TA, et al: Non-small cell lung cancer, version 3.2022, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
20:497–530. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shibata E, Kiran M, Shibata Y, Singh S,
Kiran S and Dutta A: Two subunits of human ORC are dispensable for
DNA replication and proliferation. Elife. 5:e190842016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bell SP, Kobayashi R and Stillman B: Yeast
origin recognition complex functions in transcription silencing and
DNA replication. Science. 262:1844–1849. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chesnokov IN, Chesnokova ON and Botchan M:
A cytokinetic function of Drosophila ORC6 protein resides in a
domain distinct from its replication activity. Proc Natl Acad Sci
USA. 100:9150–9155. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Semple JW, Da-Silva LF, Jervis EJ, Ah-Kee
J, Al-Attar H, Kummer L, Heikkila JJ, Pasero P and Duncker BP: An
essential role for Orc6 in DNA replication through maintenance of
pre-replicative complexes. EMBO J. 25:5150–5158. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen S, de Vries MA and Bell SP: Orc6 is
required for dynamic recruitment of Cdt1 during repeated Mcm2-7
loading. Genes Dev. 21:2897–2907. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu S, Balasov M, Wang H, Wu L, Chesnokov
IN and Liu Y: Structural analysis of human Orc6 protein reveals a
homology with transcription factor TFIIB. Proc Natl Acad Sci USA.
108:7373–7378. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Prasanth SG, Prasanth KV and Stillman B:
Orc6 involved in DNA replication, chromosome segregation, and
cytokinesis. Science. 297:1026–1031. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang XK, Wang QQ, Huang JL, Zhang LB, Zhou
X, Liu JQ, Chen ZJ, Liao XW, Huang R, Yang CK, et al: Novel
candidate biomarkers of origin recognition complex 1, 5 and 6 for
survival surveillance in patients with hepatocellular carcinoma. J
Cancer. 11:1869–1882. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pan Q, Li F, Ding Y, Huang H and Guo J:
ORC6 acts as a biomarker and reflects poor outcome in clear cell
renal cell carcinoma. J Cancer. 13:2504–2514. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Senter NC, McCulley A, Kuznetsov VA and
Feng W: Identification of recurrent chromosome breaks underlying
structural rearrangements in mammary cancer cell lines. Genes
(Basel). 13:12282022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu Y, Wang L, Li Z, Wan Z, Shao M, Wu S
and Wang G: Potential prognostic and diagnostic values of CDC6,
CDC45, ORC6 and SNHG7 in colorectal cancer. Onco Targets Ther.
12:11609–11621. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wei J, Yin Y, Deng Q, Zhou J, Wang Y, Yin
G, Yang J and Tang Y: Integrative analysis of MicroRNA and gene
interactions for revealing candidate signatures in prostate cancer.
Front Genet. 11:1762020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Y, Chen P, Li M, Fei H, Huang J, Zhao
T and Li T: Comprehensive analysis of the control of cancer stem
cell characteristics in endometrial cancer by network analysis.
Comput Math Methods Med. 2021:66532952021.PubMed/NCBI
|
|
22
|
Wang Z, Jensen MA and Zenklusen JC: A
practical guide to the cancer genome atlas (TCGA). Methods Mol
Biol. 1418:111–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
In J and Lee DK: Survival analysis: Part
II-applied clinical data analysis. Korean J Anesthesiol. 76:84–85.
2019. View Article : Google Scholar
|
|
24
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen B, Khodadoust MS, Liu CL, Newman AM
and Alizadeh AA: Profiling tumor infiltrating immune cells with
CIBERSORT. Methods Mol Biol. 1711:243–259. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hänzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q,
Li B and Liu XS: TIMER2.0 for analysis of tumor-infiltrating immune
cells. Nucleic Acids Res. 48:W509–W514. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hayford CE, Tyson DR, Robbins CJ III,
Frick PL, Quaranta V and Harris LA: An in vitro model of tumor
heterogeneity resolves genetic, epigenetic, and stochastic sources
of cell state variability. PLoS Biol. 19:e30007972021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu N, You Y, Liu C, Balasov M, Lun LT,
Geng Y, Fung CP, Miao H, Tian H, Choy TT, et al: Structural basis
of DNA replication origin recognition by human Orc6 protein binding
with DNA. Nucleic Acids Res. 48:11146–11161. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bleichert F, Botchan MR and Berger JM:
Crystal structure of the eukaryotic origin recognition complex.
Nature. 519:321–326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Balasov M, Huijbregts RP and Chesnokov I:
Role of the Orc6 protein in origin recognition complex-dependent
DNA binding and replication in Drosophila melanogaster. Mol Cell
Biol. 27:3143–3153. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thomae AW, Baltin J, Pich D, Deutsch MJ,
Ravasz M, Zeller K, Gossen M, Hammerschmidt W and Schepers A:
Different roles of the human Orc6 protein in the replication
initiation process. Cell Mol Life Sci. 68:3741–3756. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kumar M and Sarkar A: Current therapeutic
strategies and challenges in nsclc treatment: A comprehensive
review. Exp Oncol. 44:7–16. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
He D, Wang D, Lu P, Yang N, Xue Z, Zhu X,
Zhang P and Fan G: Single-cell RNA sequencing reveals heterogeneous
tumor and immune cell populations in early-stage lung
adenocarcinomas harboring EGFR mutations. Oncogene. 40:355–368.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tang M, Chen J, Zeng T, Ye DM, Li YK, Zou
J and Zhang YP: Systemic analysis of the DNA replication regulator
origin recognition complex in lung adenocarcinomas identifies
prognostic and expression significance. Cancer Med. 12:5035–5054.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gilboa E: DC-based cancer vaccines. J Clin
Invest. 117:1195–1203. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Steinman RM: Decisions about dendritic
cells: Past, present, and future. Annu Rev Immunol. 30:1–22. 2012.
View Article : Google Scholar : PubMed/NCBI
|
